Prognia
Drug Database
🇪🇺EU · EMAWithdrawn from rolling review

Bamlanivimab and etesevimab for COVID-19(bamlanivimab;Etesevimab)

Marketing Authorisation Holder: Eli Lilly Nederland B.V.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bamlanivimab and etesevimab for COVID-19 — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Bamlanivimab and etesevimab for COVID-19Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.